论文部分内容阅读
Microtubule-targeting agent Combretastatin A-4(CA-4) exerts potent cytotoxicity and good activity as vascular disrupting agents(VDAs)1.The early-phase clinical trials of the CA-4 analogues in many solid tumors have demonstrated that they have promising therapeutic benefits2.